Answer
Risankizumab selectively binds with high affinity to the p19 subunit of interleukin-23 (IL-23), without binding IL-12, preventing IL-23 from interacting with its receptor complex and thereby inhibiting IL-23-dependent cell signalling and proinflammatory cytokine release.
Sources for this answer
- Skyrizi 150 mg solution for injection in pre-filled penAbbVie Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 11Document updated
Sources checked